echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Expert: The new crown vaccine has a good protection effect on minors

    Expert: The new crown vaccine has a good protection effect on minors

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Expert: The new crown vaccine has a good protection effect on minors
    Expert: The new crown vaccine has a good protection effect on minors Expert: The new crown vaccine has a good protection effect on minors

    China News Service, Guangzhou, July 4 (Reporter Minjie Cai) A seminar on the prevention and control of vaccine-preventable diseases under the new crown epidemic was held in Guangzhou on the 4th
    .


    Zheng Huizhen, chief expert on disease control of the Guangdong Provincial Preventive Medicine Association, said in an interview during the meeting that the results of the study of healthy children and adolescents vaccinated with the new crown vaccine between the ages of 3 and 17 show that the safety and immunogenicity data are good, and the epidemic situation is serious.


    On the evening of June 28, 2021, the World Journal of Infectious Diseases "The Lancet-Infectious Diseases" magazine published online the new coronavirus inactivated vaccine developed by SINOVAC Kexing in healthy children and adolescents aged 3 to 17 The safety, tolerability and immunogenicity of vaccination are the results of a double-blind randomized controlled phase I/II clinical study
    .

    The results of the study show that among healthy children and adolescents between the ages of 3 and 17, using the 0, 28-day immunization sequence to inoculate two doses of the new crown inactivated vaccine Kellyford, which shows good safety and tolerance to this population Sex, can induce the body to produce a strong humoral immune response
    .


    The conclusions of the study support the use of 3.


    Zheng Huizhen said that the study also found that the immune response of children and adolescents was better than that of adults between 18 and 59 years old and the elderly 60 years old and above after vaccinating two doses of the medium dose (3 micrograms each) according to the same immunization schedule
    .

    Large-scale vaccination of the new crown virus vaccine is an effective means to build a population's immune barrier and prevent and control the new crown pneumonia epidemic
    .


    According to statistics, as of 24 June 30, Guangdong has vaccinated 125 041 300 times, a total of 588 7.


    7.


    Guangdong health committee will be July 1, he said full liberalization over 18 years (including 60 years of age) population vaccinated first dose of inactivated vaccine
    .

    Committee member

    "The elderly should fight as much as possible
    .


    " Zheng Huizhen said, unless there are contraindications to vaccination, the elderly who are eligible should receive the new crown pneumonia vaccine as soon as possible


    Focus on the new crown pneumonia epidemic
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.